New York, USA – November 16, 2020 – In September, the breaking news regarding the antibody-drug conjugate (ADC) drugs is Gilead’s acquisition of Immunomedics and Merck and Seattle Genetics’ strategic cooperation project. In the past two years, ADC drugs made a series of breakthroughs in the treatment of refractory cancers, ushered in a climax of research and development, and were popular for new drug approvals and transactions.
Creative Biolabs is committed to helping develop standard ADCs that are stable in the bloodstream both chemically and physiologically and have designated payload toxicological effects after internalization. With climbing funds invested in the area of ADC R&D, Creative Biolabs, as an expert in ADC development, received consecutive inquiries about its featured one-stop antibody conjugation service.
An ADC is composed of three sectors, a monoclonal antibody, a cytotoxic payload, and a small molecular linker that connects the other two parts. Creative Biolabs has a bank of payload drugs and linkers, and sophisticated skills in chemical synthesis, chemical modification, as well as bio-conjugation, competent to provide custom synthesis services according to customers’ requirements to help obtain ADC with desired properties.
ADC payload drug is an essential factor in an ADC, which is highly toxic and defines the efficacy. It can cause cell death by interacting with intracellular targets, or blocking or disrupting crucial cellular metabolic pathways. Creative Biolabs can provide drug modules that have high cytotoxic efficacy and maintain drug efficacy in plasma.
* Microtubule toxins, DNA toxins, transcription toxins, nanocarriers, protein toxins, toxic enzymes/ADEPT, inhibitors, etc.
Linkers, determining the structure of the drug molecule, should be stable in systemic circulation and could release the payload timely when reaching the target. Designing linker should consider the following aspects, the biology of the target cells, the characteristics of the antibody, and the structure of the drug molecule. Creative Biolabs, possessing the exclusive “DrugLnk” organic synthesis platform, offers both cleavable/non-cleavable linker products, drug-linker complex products, and linker design service to help customers obtain satisfactory solutions.
* pH-sensitive (acid-labile) linkers, disulfide linkers, protease-sensitive (peptide) linkers, ß-glucuronide linkers.
Relying on the “DrugLnk” organic synthesis platform, the technicians are skilled at custom synthesis to assemble the optimal ADC molecules that are passed on to the assessment of their biochemical characteristics (structural analysis, ADC stability analysis, drug antibody ratio determination, and conjugate site analysis), in vitro efficacy (ADC affinity evaluation, internalization assays, cytotoxicity assays, etc.), and behavior and cytotoxicity by 3D cultured cells.
Creative Biolabs can customize the service flow upon requests, which is fully supported by professional scientists. Visit the official website https://www.creative-biolabs.com/adc to learn more.
Creative Biolabs is a leading solution provider in ADC, which keeps offering standard products and comprehensive technical support to global pharmaceutical companies, research institutes, and universities. After years of exploration, Creative Biolabs has accumulated rich experience and good praise in the industry.